Clinical Trial Details
EORTC-62027
Back to Clinical Trials Database
Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22) (q22;q13) translocation resulting in a COL1A1/PDGF- beta fusion protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)
| Trial Status | All trial activities ended |
|---|---|
| Dates |
Date of activation: 27-Apr-2004 Date Step1 close: 02-Apr-2007 Date Step2 close: 08-May-2007 |
| Data management at EORTC | Yes |
| Design |
Phase 2 Randomized open label |
| Targeted Sample size | EORTC Groups: 44 |
| Treatment | |
| Study Staff | |
| Type of cancer | |
| Participating groups | |
| Protocol summary | http://clinicaltrials.gov/study/NCT00085475 |
| NCT number | NCT00085475 |
| EudraCT | 2004-002538-20 |
